 MONMOUTH JUNCTION, N.J., Nov. 19, 2020 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the creation of its Global Retina Advisory Council. Mark Humayun, MD, PhD, has agreed to act as Chairman of the Advisory Council and Firas Rahhal, MD, has agreed to join him as an inaugural member. 